CA2309033C - Emulsions specifiques de glandes lacrymales pour application topique sur le tissu oculaire - Google Patents

Emulsions specifiques de glandes lacrymales pour application topique sur le tissu oculaire Download PDF

Info

Publication number: CA2309033C
Authority: CA; Canada
Prior art keywords: cyclosporin; emulsion; polysorbate; castor oil; pharmaceutical composition
Prior art date: 1994-05-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002309033A

Other languages

English (en)

Other versions

CA2309033A1 (fr

Inventor

Shulin Ding

Walter L. Tien

Orest Olejnik

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Allergan Inc

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-17

Filing date

1995-05-17

Publication date

2003-08-26

1994-05-17 Priority claimed from US08/243,279 external-priority patent/US5474979A/en

1995-05-17 Application filed by Allergan Inc filed Critical Allergan Inc

1995-11-23 Publication of CA2309033A1 publication Critical patent/CA2309033A1/fr

2003-08-26 Application granted granted Critical

2003-08-26 Publication of CA2309033C publication Critical patent/CA2309033C/fr

2015-05-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

210000001519 tissue Anatomy 0.000 title claims abstract description 31
239000000839 emulsion Substances 0.000 title claims abstract description 27
210000004561 lacrimal apparatus Anatomy 0.000 title claims abstract description 23
230000000699 topical effect Effects 0.000 title claims description 12
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 92
229960001265 ciclosporin Drugs 0.000 claims abstract description 92
108010036949 Cyclosporine Proteins 0.000 claims abstract description 91
229930105110 Cyclosporin A Natural products 0.000 claims abstract description 90
229930182912 cyclosporin Natural products 0.000 claims abstract description 69
239000000203 mixture Substances 0.000 claims abstract description 56
239000004359 castor oil Substances 0.000 claims abstract description 34
235000019438 castor oil Nutrition 0.000 claims abstract description 34
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 34
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract description 22
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 22
229940068968 polysorbate 80 Drugs 0.000 claims abstract description 22
229920000053 polysorbate 80 Polymers 0.000 claims abstract description 22
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 13
239000000194 fatty acid Substances 0.000 claims abstract description 13
229930195729 fatty acid Natural products 0.000 claims abstract description 13
238000010521 absorption reaction Methods 0.000 claims abstract description 11
229940079593 drug Drugs 0.000 claims abstract description 10
239000003814 drug Substances 0.000 claims abstract description 10
231100000344 non-irritating Toxicity 0.000 claims abstract description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
235000011187 glycerol Nutrition 0.000 claims description 5
229960000905 indomethacin Drugs 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
230000001804 emulsifying effect Effects 0.000 claims description 2
239000008251 pharmaceutical emulsion Substances 0.000 claims 4
125000005456 glyceride group Chemical group 0.000 claims 1
230000000087 stabilizing effect Effects 0.000 claims 1
230000007794 irritation Effects 0.000 abstract description 7
238000002425 crystallisation Methods 0.000 abstract description 5
230000008025 crystallization Effects 0.000 abstract description 4
238000002483 medication Methods 0.000 abstract description 3
238000009472 formulation Methods 0.000 description 40
210000001508 eye Anatomy 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
241000283973 Oryctolagus cuniculus Species 0.000 description 12
230000000694 effects Effects 0.000 description 11
239000003921 oil Substances 0.000 description 10
235000019198 oils Nutrition 0.000 description 10
108010036941 Cyclosporins Proteins 0.000 description 8
239000000243 solution Substances 0.000 description 8
208000003556 Dry Eye Syndromes Diseases 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
210000001742 aqueous humor Anatomy 0.000 description 5
239000003995 emulsifying agent Substances 0.000 description 5
238000011282 treatment Methods 0.000 description 5
206010013774 Dry eye Diseases 0.000 description 4
229920002125 Sokalan® Polymers 0.000 description 4
239000003125 aqueous solvent Substances 0.000 description 4
210000004087 cornea Anatomy 0.000 description 4
-1 for example Substances 0.000 description 4
238000005567 liquid scintillation counting Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
238000002485 combustion reaction Methods 0.000 description 3
210000000795 conjunctiva Anatomy 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
235000008390 olive oil Nutrition 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
239000000126 substance Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
UCOQITKXMNKTKF-MXGZYYNMSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28,30-decamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C)NC1=O UCOQITKXMNKTKF-MXGZYYNMSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
229920002675 Polyoxyl Polymers 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
229960001631 carbomer Drugs 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
210000000744 eyelid Anatomy 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000001861 immunosuppressant effect Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229950008882 polysorbate Drugs 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
230000035807 sensation Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
239000003643 water by type Substances 0.000 description 2
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical class C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
DSEKYWAQQVUQTP-UHFFFAOYSA-N Cerin Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CC(O)C(=O)C2C DSEKYWAQQVUQTP-UHFFFAOYSA-N 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000005100 Herpetic Keratitis Diseases 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
206010020864 Hypertrichosis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
206010052143 Ocular discomfort Diseases 0.000 description 1
208000023715 Ocular surface disease Diseases 0.000 description 1
206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
125000005250 alkyl acrylate group Chemical group 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
239000000607 artificial tear Substances 0.000 description 1
239000012496 blank sample Substances 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000004240 ciliary body Anatomy 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
231100000478 corneal permeability Toxicity 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
108010019249 cyclosporin G Proteins 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
210000003717 douglas' pouch Anatomy 0.000 description 1
229940009662 edetate Drugs 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229960001048 fluorometholone Drugs 0.000 description 1
FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
235000013305 food Nutrition 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
229940057917 medium chain triglycerides Drugs 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229960002800 prednisolone acetate Drugs 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
229940075554 sorbate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
239000008399 tap water Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CA002309033A 1994-05-17 1995-05-17 Emulsions specifiques de glandes lacrymales pour application topique sur le tissu oculaire Expired - Lifetime CA2309033C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/243,279 US5474979A (en)	1994-05-17	1994-05-17	Nonirritating emulsions for sensitive tissue
US08/243,279		1994-05-17
CA002190485A CA2190485C (fr)	1994-05-17	1995-05-17	Emulsion specifique de la glande lacrymale pour application locale sur les tissus de l'oeil

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002190485A Division CA2190485C (fr)	1994-05-17	1995-05-17	Emulsion specifique de la glande lacrymale pour application locale sur les tissus de l'oeil

Publications (2)

Publication Number	Publication Date
CA2309033A1 CA2309033A1 (fr)	1995-11-23
CA2309033C true CA2309033C (fr)	2003-08-26

Family

ID=25678827

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002309033A Expired - Lifetime CA2309033C (fr)	1994-05-17	1995-05-17	Emulsions specifiques de glandes lacrymales pour application topique sur le tissu oculaire

Country Status (1)

Country	Link
CA (1)	CA2309033C (fr)

1995
- 1995-05-17 CA CA002309033A patent/CA2309033C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2309033A1 (fr)	1995-11-23

Legal Events

Date	Code	Title	Description
2000-05-30	EEER	Examination request
2015-07-21	MKEX	Expiry	Effective date: 20150519

Publication	Publication Date	Title
CA2190485C (fr)	2003-04-15	Emulsion specifique de la glande lacrymale pour application locale sur les tissus de l'oeil
US5182258A (en)	1993-01-26	Systemic delivery of polypeptides through the eye
US4990337A (en)	1991-02-05	Cyclosporin formulations of mono or diglyceride fatty acid
RU2331423C2 (ru)	2008-08-20	Система доставки с контролируемым высвобождением для назального применения
US5951971A (en)	1999-09-14	Ophthalmic compositions
KR20100107462A (ko)	2010-10-05	안정한 수성 시클로스포린 조성물
KR20090053797A (ko)	2009-05-27	사이클로스포린 조성물
SK282714B6 (sk)	2002-11-06	Hydrofilné binárne systémy na podávanie cyklosporínu
US5278142A (en)	1994-01-11	Systemic delivery of polypeptides through the eye
US20150045309A1 (en)	2015-02-12	Cyclosporin emulsions
AU2003247976A1 (en)	2004-08-10	Ophthalmic compositions containing loratadine
CA2309033C (fr)	2003-08-26	Emulsions specifiques de glandes lacrymales pour application topique sur le tissu oculaire
MXPA96005599A (en)	1998-11-12	Specific emulsions for the lagrimal gland, for the topic application to the ocu tissue
Tsuji et al.	1987	Hydrolysis of prednisolone succinate by esterase in rabbit ocular tissue
JP2632010B2 (ja)	1997-07-16	シクロスポリン製剤
US6225332B1 (en)	2001-05-01	Compositions containing histamine H2 agonists and methods of use in treating allergy and inflammation
HK1034190B (en)	2005-12-09	Lacrimal gland specific emulsions for topical application to ocular tissue
RU2634267C2 (ru)	2017-10-24	Водный офтальмологический раствор на основе циклоспорина a
HK1183443B (en)	2017-02-03	Cyclosporin emulsions
MXPA06005325A (en)	2006-10-17	Controlled release delivery system for nasal applications